| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Commercial Platform | | | | | 30.4 | 17.2 | | |
| Global Supply Chain Platform | | | | | 31.3 | 28.4 | | 18.0 |
| Other | | | | | 27.4 | | | |
| Total revenues [+] | 102.8 | 95.4 | 144.4 | 101.2 | 89.1 | 38.0 | 20.6 | 13.9 |
| Licensing | | | | | | | | 0.3 |
| Products | | | | | | | | 12.8 |
| Grants | | | | | | | | 0.8 |
| Revenue growth [+] | 7.8% | -34.0% | 42.6% | 13.6% | 134.2% | 85.1% | 47.4% | |
| Commercial Platform | | | | | 76.7% | | | |
| Global Supply Chain Platform | | | | | 10.0% | | | |
| Oncology Innovation Platform | | | | | 2222.9% | | | |
| Cost of goods sold | 76.1 | 62.9 | 95.4 | 69.6 | 47.0 | 25.1 | 19.7 | 13.2 |
| Gross profit | 26.7 | 32.5 | 49.0 | 31.6 | 42.1 | 12.9 | 0.8 | 0.8 |
| Gross margin | 26.0% | 34.1% | 34.0% | 31.2% | 47.2% | 34.0% | 4.1% | 5.7% |
| Selling, general and administrative | 96.7 | 182.9 | 168.8 | 150.7 | 49.0 | 46.1 | 26.0 | 27.0 |
| Research and development | | | | | 119.9 | 76.8 | 60.6 | 24.5 |
| Other operating expenses | -0.1 | -41.0 | | | | | | |
| EBITDA [+] | -65.5 | -104.4 | -115.2 | -115.2 | -123.5 | -106.3 | -83.7 | -49.8 |
| EBITDA growth | -37.3% | -9.4% | 0.0% | -6.7% | 16.2% | 27.0% | 68.0% | |
| EBITDA margin | -63.7% | -109.5% | -79.8% | -113.8% | -138.7% | -279.5% | -407.4% | -357.3% |
| Depreciation | 3.3 | 3.2 | 2.7 | 1.9 | 1.7 | 2.1 | 1.2 | 0.5 |
| EBITA | -68.7 | -107.6 | -117.9 | -117.1 | -125.2 | -108.4 | -84.9 | -50.3 |
| EBITA margin | -66.8% | -112.8% | -81.7% | -115.7% | -140.5% | -284.9% | -413.3% | -360.8% |
| Amortization of intangibles | 1.2 | 1.8 | 1.8 | 1.9 | 1.6 | 1.6 | 0.8 | 0.4 |
| EBIT [+] | -69.9 | -109.4 | -119.7 | -119.0 | -126.8 | -110.0 | -85.7 | -50.7 |
| EBIT growth | -36.1% | -8.6% | 0.6% | -6.1% | 15.3% | 28.3% | 69.1% | |
| EBIT margin | -68.0% | -114.7% | -82.9% | -117.6% | -142.3% | -289.1% | -417.2% | -363.7% |
| Non-recurring items [+] | 0.1 | 41.0 | | | | | | |
| Asset impairment | 0.1 | 41.0 | | | | | | |
| Interest expense, net [+] | -0.4 | -0.1 | -0.9 | -1.9 | 1.8 | 5.9 | 1.9 | 0.0 |
| Interest expense | 25.8 | 20.7 | 11.2 | 7.0 | 3.6 | 6.3 | 1.9 | 0.0 |
| Interest income | 0.4 | 0.1 | 0.9 | 1.9 | 1.8 | 0.4 | | |
| Other income (expense), net | -3.1 | | -10.3 | | | -15.4 | -0.5 | |
| Pre-tax income | -98.6 | -171.0 | -140.4 | -124.1 | -128.6 | -131.3 | -88.2 | -50.7 |
| Income taxes | 0.3 | -10.6 | 4.1 | 0.9 | 0.1 | 0.1 | -0.3 | -0.1 |
| Tax rate | | 6.2% | | | | | 0.3% | 0.1% |
| Minority interest | | | | | -11.3 | -0.2 | -0.2 | -0.1 |
| Earnings from continuing ops | -99.0 | -160.4 | -144.4 | -125.0 | -117.4 | -131.2 | -87.7 | -50.6 |
| Earnings from discontinued ops | -5.4 | -41.7 | -4.0 | -0.5 | | | | |
| Net income | -103.4 | -199.8 | -146.2 | -123.7 | -117.4 | -131.2 | -87.7 | -50.6 |
| Net margin | -100.6% | -209.5% | -101.2% | -122.2% | -131.8% | -344.8% | -426.8% | -362.9% |
| |
| Basic EPS [+] | ($15.13) | ($30.86) | ($1.70) | ($1.69) | ($1.82) | ($2.63) | ($2.19) | ($1.50) |
| Growth | -51.0% | 1717.6% | 0.5% | -7.1% | -30.7% | 20.1% | 45.9% | |
| Diluted EPS [+] | ($15.13) | ($30.86) | ($1.70) | ($1.69) | ($1.82) | ($2.63) | ($2.19) | ($1.50) |
| Growth | -51.0% | 1717.6% | 0.5% | -7.1% | -30.7% | 20.1% | 45.9% | |
| |
| Shares outstanding (basic) [+] | 6.5 | 5.2 | 85.1 | 74.1 | 64.6 | 50.0 | 40.1 | 33.8 |
| Growth | 25.9% | -93.9% | 14.9% | 14.7% | 29.3% | 24.5% | 18.8% | |
| Shares outstanding (diluted) [+] | 6.5 | 5.2 | 85.1 | 74.1 | 64.6 | 50.0 | 40.1 | 33.8 |
| Growth | 25.9% | -93.9% | 14.9% | 14.7% | 29.3% | 24.5% | 18.8% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |